Cargando…
Progress in oncolytic viruses modified with nanomaterials for intravenous application
In oncolytic virus (OV) therapy, a critical component of tumor immunotherapy, viruses selectively infect, replicate within, and eventually destroy tumor cells. Simultaneously, this therapy activates immune responses and mobilizes immune cells, thereby eliminating residual or distant cancer cells. Ho...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690878/ https://www.ncbi.nlm.nih.gov/pubmed/38009779 http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0275 |
_version_ | 1785152615456178176 |
---|---|
author | Chen, Liting Ma, Zhijun Xu, Chen Xie, Youbang Ouyang, Defang Song, Shuhui Zhao, Xiao Liu, Funan |
author_facet | Chen, Liting Ma, Zhijun Xu, Chen Xie, Youbang Ouyang, Defang Song, Shuhui Zhao, Xiao Liu, Funan |
author_sort | Chen, Liting |
collection | PubMed |
description | In oncolytic virus (OV) therapy, a critical component of tumor immunotherapy, viruses selectively infect, replicate within, and eventually destroy tumor cells. Simultaneously, this therapy activates immune responses and mobilizes immune cells, thereby eliminating residual or distant cancer cells. However, because of OVs’ high immunogenicity and immune clearance during circulation, their clinical applications are currently limited to intratumoral injections, and their use is severely restricted. In recent years, numerous studies have used nanomaterials to modify OVs to decrease virulence and increase safety for intravenous injection. The most commonly used nanomaterials for modifying OVs are liposomes, polymers, and albumin, because of their biosafety, practicability, and effectiveness. The aim of this review is to summarize progress in the use of these nanomaterials in preclinical experiments to modify OVs and to discuss the challenges encountered from basic research to clinical application. |
format | Online Article Text |
id | pubmed-10690878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Compuscript |
record_format | MEDLINE/PubMed |
spelling | pubmed-106908782023-12-02 Progress in oncolytic viruses modified with nanomaterials for intravenous application Chen, Liting Ma, Zhijun Xu, Chen Xie, Youbang Ouyang, Defang Song, Shuhui Zhao, Xiao Liu, Funan Cancer Biol Med Review In oncolytic virus (OV) therapy, a critical component of tumor immunotherapy, viruses selectively infect, replicate within, and eventually destroy tumor cells. Simultaneously, this therapy activates immune responses and mobilizes immune cells, thereby eliminating residual or distant cancer cells. However, because of OVs’ high immunogenicity and immune clearance during circulation, their clinical applications are currently limited to intratumoral injections, and their use is severely restricted. In recent years, numerous studies have used nanomaterials to modify OVs to decrease virulence and increase safety for intravenous injection. The most commonly used nanomaterials for modifying OVs are liposomes, polymers, and albumin, because of their biosafety, practicability, and effectiveness. The aim of this review is to summarize progress in the use of these nanomaterials in preclinical experiments to modify OVs and to discuss the challenges encountered from basic research to clinical application. Compuscript 2023-11-15 2023-11-24 /pmc/articles/PMC10690878/ /pubmed/38009779 http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0275 Text en Copyright: © 2023, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Chen, Liting Ma, Zhijun Xu, Chen Xie, Youbang Ouyang, Defang Song, Shuhui Zhao, Xiao Liu, Funan Progress in oncolytic viruses modified with nanomaterials for intravenous application |
title | Progress in oncolytic viruses modified with nanomaterials for intravenous application |
title_full | Progress in oncolytic viruses modified with nanomaterials for intravenous application |
title_fullStr | Progress in oncolytic viruses modified with nanomaterials for intravenous application |
title_full_unstemmed | Progress in oncolytic viruses modified with nanomaterials for intravenous application |
title_short | Progress in oncolytic viruses modified with nanomaterials for intravenous application |
title_sort | progress in oncolytic viruses modified with nanomaterials for intravenous application |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690878/ https://www.ncbi.nlm.nih.gov/pubmed/38009779 http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0275 |
work_keys_str_mv | AT chenliting progressinoncolyticvirusesmodifiedwithnanomaterialsforintravenousapplication AT mazhijun progressinoncolyticvirusesmodifiedwithnanomaterialsforintravenousapplication AT xuchen progressinoncolyticvirusesmodifiedwithnanomaterialsforintravenousapplication AT xieyoubang progressinoncolyticvirusesmodifiedwithnanomaterialsforintravenousapplication AT ouyangdefang progressinoncolyticvirusesmodifiedwithnanomaterialsforintravenousapplication AT songshuhui progressinoncolyticvirusesmodifiedwithnanomaterialsforintravenousapplication AT zhaoxiao progressinoncolyticvirusesmodifiedwithnanomaterialsforintravenousapplication AT liufunan progressinoncolyticvirusesmodifiedwithnanomaterialsforintravenousapplication |